CRBU Q1 2022 Earnings — Caribou Biosciences, Inc. Revenue & Financial Results | Market Cap Arena

CRBUCaribou Biosciences, Inc.

$186M

Q1 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$3M+68.0% YoY

Gross Profit

-$11M-422.7% margin

Operating Income

-$21M-782.8% margin

Net Income

-$19M-716.5% margin

EPS (Diluted)

$-0.32

QoQ Revenue Growth

+4.1%

Cash Flow

Operating Cash Flow

-$22M

Free Cash Flow

-$22M

Stock-Based Comp.

$3M

Balance Sheet

Total Assets

$446M

Total Liabilities

$74M

Stockholders' Equity

$372M

Cash & Equivalents

$148M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$3M	$2M	+68.0%
Gross Profit	-$11M	-$9M	-31.3%
Operating Income	-$21M	-$13M	-58.3%
Net Income	-$19M	-$13M	-45.1%

Geographic Segments

UNITED STATES

$3M98%

Non-US

$52,0002%